secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001628280-25-042245
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Phase 1 cemsidomide shows 50% ORR at 100 µg in RRMM; Phase 2 planned Q1 2026
--------------------------------------------------------------------------------

- 50% ORR at 100 µg and 40% ORR at 75 µg cemsidomide + dex in heavily pre-treated RRMM; median DOR 9.3 mo overall.
- No cemsidomide-related discontinuations; minimal dose reductions (6%); low rates of febrile neutropenia (4% Grade 3, 1% Grade 4).
- Phase 2 single-arm registrational trial in 4th line+ starts Q1 2026; Phase 1b with BCMA BiTE in 2nd line+ starts Q2 2026.
- 72 patients enrolled; median 7 prior therapies; 75% had prior CAR-T or T-cell engager therapy; data cutoff July 23, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025042245/0001628280-25-042245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025042245/cccc-20250922.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-042245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer